Canakinumab is an anti-IL-1β neutralizing monoclonal antibody and has shown efficacy in RA and systemic juvenile idiopathic arthritis but no benefit for recent onset T1D patients (285, 296). The gene discussed is IL1B; the disease is rheumatoid arthritis.